权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer

靶向 B7-H3 治疗去势抵抗性前列腺癌的新方法

基本信息

批准号：
10560840
负责人：
Di Zhao
金额：
$ 58.81万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-01-01 至 2027-12-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10560840
关键词：
Antiandrogen Therapy Antibody-drug conjugates Biological Biological Process Biology CD276 gene CTLA4 blockade Cancer Patient Cells Clinical Combination immunotherapy Complex Cytometry Data Defect Development Disease Disease Progression Gene Deletion Genetically Engineered Mouse Goals Human Immune Impairment In Vitro Infiltration Malignant Neoplasms Malignant neoplasm of prostate Mediating Molecular Monoclonal Antibodies Mutation Myeloid Cells Myeloid-derived suppressor cells Nature Outcome PTEN gene Pathway interactions Patients Phenotype Pilot Projects Play Pre-Clinical Model Prostate RB1 gene Recurrent Malignant Neoplasm Research Resistance Role Signal Pathway Signal Transduction T cell infiltration T-Lymphocyte TP53 gene Testing Therapeutic Time Tumor-associated macrophages Variant advanced prostate cancer androgen deprivation therapy antitumor effect biomarker driven cancer cell cancer recurrence castration resistant prostate cancer checkpoint therapy clinically relevant immune checkpoint in vivo inhibitor molecular marker molecular subtypes mouse model novel novel strategies overexpression patient derived xenograft model predicting response predictive marker programmed cell death protein 1 prostate cancer model prostate cancer progression receptor response targeted treatment therapy resistant tool transcriptomic profiling transcriptomics tumor tumor microenvironment

项目摘要

ABSTRACT More than 60% of metastatic castration-resistant prostate cancers (CRPC) contain PTEN and TP53 gene deletions and mutations. To date, there are limited treatment options for this molecular subtype. The overall objective of this application is to elucidate the complex role of B7-H3 signaling in prostate cancer (PCa) as well as develop biomarker-driven B7-H3 targeted therapy for CRPC. Our preliminary studies demonstrated that PTEN/TP53 defects induce B7-H3 overexpression and that depletion of B7-H3 in cancer cells remarkably impaired progression of PTEN/p53-deficient PCa in vivo. Mass cytometry analysis revealed that B7-H3 signaling is involved in modulating immunosuppressive myeloid cells in the PCa tumor microenvironment (TME). Here, the central hypothesis is that B7-H3 signaling contributes to the progression of PCa containing PTEN/p53 deficiencies and plays a key role in reprogramming immunosuppressive myeloid cells in the PCa TME. The central hypothesis will be tested by pursuing the following specific aims. Aim 1. Elucidate B7-H3’s impact on progression of advanced PCa containing PTEN/TP53 loss. The hypothesis in this aim is that B7-H3 plays a key role in PCa progression and resistance to ADT and that PTEN/TP53 defects render CRPC more responsive to B7-H3 targeted therapy. To this end, we have generated a novel GEMM with prostate-specific co-deletion of Pten/Trp53/Cd276. This state-of-the-art spontaneous GEMM provides a unique tool to dissect the role of B7-H3 signaling in PCa development and therapeutic resistance. Mechanistic studies will illuminate how PTEN and p53 pathways control B7-H3 expression. Clinical relevance among B7-H3 expression, PTEN/TP53 status, and disease progression will be assessed in human CRPCs. B7-H3 targeted therapies will also be tested in various preclinical models of metastatic CRPC containing PTEN/TP53 loss. Aim 2. Understand how B7-H3 signaling modulates immunosuppressive myeloid cells in CRPC. The hypothesis is that B7-H3 signaling contributes to the reprogramming of myeloid cells in the PCa TME. Single-cell transcriptomics analysis will be performed in above GEMMs. Functional studies will address how B7-H3 signaling mediates the crosstalk between cancer cells and immunosuppressive myeloid cells. B7-H3 receptor(s) and the downstream signaling pathway(s) in myeloid cells will also be characterized. Finally, the therapeutic potential of co-targeting B7-H3 and immunosuppressive myeloid cells will be evaluated in preclinical models of CRPC. These studies are expected to have significant positive impacts, including advancing the understanding of B7-H3 biology in cancers and providing a compelling rationale for the use of PTEN and TP53 defects as molecular biomarkers for predicting response to B7-H3-targeted therapy for patients with CRPC. The proposed research will also establish, for the first time, the role of B7-H3 signaling in reprogramming myeloid cells in the TME and develop effective combinatorial immunotherapy targeting B7-H3.

摘要